License Agreements - Lilly (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended		178 Months Ended
	Dec. 31, 2009	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024
License Agreements
Total revenues		$ 1,137,871	$ 919,025	$ 3,062,519	$ 2,682,308
Eli Lilly | OLUMIANT
License Agreements
Total revenues		$ 34,800	$ 29,600	$ 97,100	$ 95,800
Development Milestones | Eli Lilly
License Agreements
Amount recognized and received for the achievement of a predefined milestone						$ 149,000
Development Milestones | Maximum | Eli Lilly
License Agreements
Upfront and immediate milestone payment to be received under license agreement	$ 150,000
Regulatory Milestones | Eli Lilly
License Agreements
Amount recognized and received for the achievement of a predefined milestone						335,000
Regulatory Milestones | Maximum | Eli Lilly
License Agreements
Upfront and immediate milestone payment to be received under license agreement	365,000
Commercialization Milestones | Eli Lilly
License Agreements
Amount recognized and received for the achievement of a predefined milestone						$ 50,000
Commercialization Milestones | Maximum | Eli Lilly
License Agreements
Upfront and immediate milestone payment to be received under license agreement	$ 150,000